Cargando…

Diagnosis and Therapeutic Management of Liver Fibrosis by MicroRNA

Remarkable progress has been made in the treatment and control of hepatitis B and C viral infections. However, fundamental treatments for diseases in which liver fibrosis is a key factor, such as cirrhosis, alcoholic/nonalcoholic steatohepatitis, autoimmune hepatitis, primary biliary cholangitis, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Tadokoro, Tomoko, Morishita, Asahiro, Masaki, Tsutomu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8347497/
https://www.ncbi.nlm.nih.gov/pubmed/34360904
http://dx.doi.org/10.3390/ijms22158139
_version_ 1783735103842680832
author Tadokoro, Tomoko
Morishita, Asahiro
Masaki, Tsutomu
author_facet Tadokoro, Tomoko
Morishita, Asahiro
Masaki, Tsutomu
author_sort Tadokoro, Tomoko
collection PubMed
description Remarkable progress has been made in the treatment and control of hepatitis B and C viral infections. However, fundamental treatments for diseases in which liver fibrosis is a key factor, such as cirrhosis, alcoholic/nonalcoholic steatohepatitis, autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis, are still under development and remain an unmet medical need. To solve this problem, it is essential to elucidate the pathogenesis of liver fibrosis in detail from a molecular and cellular perspective and to develop targeted therapeutic agents based on this information. Recently, microRNAs (miRNAs), functional RNAs of 22 nucleotides, have been shown to be involved in the pathogenesis of liver fibrosis. In addition, extracellular vesicles called “exosomes” have been attracting attention, and research is being conducted to establish noninvasive and extremely sensitive biomarkers using miRNAs in exosomes. In this review, we summarize miRNAs directly involved in liver fibrosis, miRNAs associated with diseases leading to liver fibrosis, and miRNAs related to complications of cirrhosis. We will also discuss the efficacy of each miRNA as a biomarker of liver fibrosis and pathology, and its potential application as a therapeutic agent.
format Online
Article
Text
id pubmed-8347497
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83474972021-08-08 Diagnosis and Therapeutic Management of Liver Fibrosis by MicroRNA Tadokoro, Tomoko Morishita, Asahiro Masaki, Tsutomu Int J Mol Sci Review Remarkable progress has been made in the treatment and control of hepatitis B and C viral infections. However, fundamental treatments for diseases in which liver fibrosis is a key factor, such as cirrhosis, alcoholic/nonalcoholic steatohepatitis, autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis, are still under development and remain an unmet medical need. To solve this problem, it is essential to elucidate the pathogenesis of liver fibrosis in detail from a molecular and cellular perspective and to develop targeted therapeutic agents based on this information. Recently, microRNAs (miRNAs), functional RNAs of 22 nucleotides, have been shown to be involved in the pathogenesis of liver fibrosis. In addition, extracellular vesicles called “exosomes” have been attracting attention, and research is being conducted to establish noninvasive and extremely sensitive biomarkers using miRNAs in exosomes. In this review, we summarize miRNAs directly involved in liver fibrosis, miRNAs associated with diseases leading to liver fibrosis, and miRNAs related to complications of cirrhosis. We will also discuss the efficacy of each miRNA as a biomarker of liver fibrosis and pathology, and its potential application as a therapeutic agent. MDPI 2021-07-29 /pmc/articles/PMC8347497/ /pubmed/34360904 http://dx.doi.org/10.3390/ijms22158139 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Tadokoro, Tomoko
Morishita, Asahiro
Masaki, Tsutomu
Diagnosis and Therapeutic Management of Liver Fibrosis by MicroRNA
title Diagnosis and Therapeutic Management of Liver Fibrosis by MicroRNA
title_full Diagnosis and Therapeutic Management of Liver Fibrosis by MicroRNA
title_fullStr Diagnosis and Therapeutic Management of Liver Fibrosis by MicroRNA
title_full_unstemmed Diagnosis and Therapeutic Management of Liver Fibrosis by MicroRNA
title_short Diagnosis and Therapeutic Management of Liver Fibrosis by MicroRNA
title_sort diagnosis and therapeutic management of liver fibrosis by microrna
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8347497/
https://www.ncbi.nlm.nih.gov/pubmed/34360904
http://dx.doi.org/10.3390/ijms22158139
work_keys_str_mv AT tadokorotomoko diagnosisandtherapeuticmanagementofliverfibrosisbymicrorna
AT morishitaasahiro diagnosisandtherapeuticmanagementofliverfibrosisbymicrorna
AT masakitsutomu diagnosisandtherapeuticmanagementofliverfibrosisbymicrorna